WZ 4002

Key Product Details

Product Description

WZ 4002 is a potent irreversible mutant selective EGFR tyrosine kinase inhibitor. It blocks ATP-dependent autophosphorylation of EGFR carrying the T790M or L858R mutation (IC₅₀ = 8 nM). WZ 4002 exhibits selectivity for mutant EGFR over wild-type. In mice bearing T790M mutant lung cancer cell lines WZ 4002 inhibits EGFR, AKT and ERK1/2 phosphorylation and results in significant tumor regression.

Licensing Information

Sold under license from Dana-Farber Cancer Institute.

Product Specifications for WZ 4002

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for WZ 4002

The following data is based on the product molecular weight 494.98.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	20.20 mL	101.01 mL	202.03 mL
0.5 mM	4.04 mL	20.20 mL	40.41 mL
1 mM	2.02 mL	10.10 mL	20.20 mL
5 mM	0.40 mL	2.02 mL	4.04 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Zhou Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009 PMID: 20033049

Product Documents for WZ 4002